Citigroup upgraded shares of Gilead Sciences (NASDAQ:GILD - Free Report) to a strong-buy rating in a research report report published on Wednesday,Zacks.com reports.
GILD has been the topic of a number of other reports. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Barclays raised their price target on Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a report on Thursday, November 7th. Cantor Fitzgerald upped their price objective on Gilead Sciences from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Finally, Oppenheimer raised their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $93.86.
Get Our Latest Research Report on Gilead Sciences
Gilead Sciences Price Performance
NASDAQ:GILD traded down $3.71 on Wednesday, reaching $88.40. 11,372,248 shares of the company's stock traded hands, compared to its average volume of 7,102,069. The stock has a 50-day simple moving average of $86.49 and a 200-day simple moving average of $75.81. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $98.90. The firm has a market cap of $110.17 billion, a PE ratio of 1,007.67, a P/E/G ratio of 2.85 and a beta of 0.17. The company has a quick ratio of 0.82, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the company earned $2.29 EPS. The firm's quarterly revenue was up 7.0% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences will post 4.39 earnings per share for the current year.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 3,422.22%.
Insider Transactions at Gilead Sciences
In related news, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Merdad Parsey sold 25,590 shares of the business's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company's stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of GILD. Kovitz Investment Group Partners LLC grew its holdings in Gilead Sciences by 8.7% in the third quarter. Kovitz Investment Group Partners LLC now owns 97,505 shares of the biopharmaceutical company's stock worth $8,175,000 after purchasing an additional 7,801 shares during the last quarter. Voya Financial Advisors Inc. acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $215,000. Wellington Management Group LLP grew its stake in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. Weiss Asset Management LP acquired a new position in shares of Gilead Sciences in the third quarter valued at about $1,677,000. Finally, State Street Corp raised its stake in shares of Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after purchasing an additional 841,776 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
